BioCentury | Oct 21, 2020
Regulation

Ethics arising from EUAs could disrupt COVID-19 vaccine trials

FDA and its vaccines advisory committee are facing ethical and practical conundrums that, unless they are resolved quickly, threaten to undermine the development of COVID-19 vaccines. The most pressing challenge centers on whether it is...
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

Casdin leads $65M round for AbSciProtein manufacturing company AbSci LLC said it raised $65 million in a series E round led by Casdin Capital. First-time backers Redmile Group and ArrowMark Partners joined returning investor Phoenix...
BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

SARS-CoV-2 infects brain choroid plexusA team from Medical Research Council Laboratory of Molecular Biology (MRC LMB) have found that SARS-CoV-2 infects the CSF-producing brain choroid plexus — but not...
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

EMA’s CHMP has backed autologous cells therapies Tecartus, from Gilead, and Lebmeldy, from Orchard, in its October set of opinions. The agency recommended conditional marketing approval for Tecartus brexucabtagene autoleucel from the Kite Pharma Inc....
BioCentury | Oct 17, 2020
Finance

Menlo to continue healthcare push at intersection of tech, life sciences with $500M fund

Greg Yap joined Menlo Ventures three years ago to ramp up the firm’s healthcare focus after a 20-year hiatus. Menlo apparently liked what it saw as Yap and his colleagues have $500 million to deploy from...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...cell disease or diabetic nephropathy. Two other programs aim...
...targets in heart failure as well. Three programs aim...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from  a series of individual success stories to a broadly applicable platform technology for cancer. The company...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...fund. The vehicle launched in 2018 as one of the first crossover funds in Europe, with the aim...
BioCentury | Oct 13, 2020
Product Development

$1B AMR Action Fund to assess first investments in 1Q21

The $1 billion AMR Action Fund remains on track to begin assessing investment opportunities in 1Q21 aimed at addressing antimicrobial resistance. In July, 23 pharmas banded together to create the fund to bridge the gap between Phase...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

The failure of Gossamer’s lead program in two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2, but the company believes further analysis of one study’s data still points...
Items per page:
1 - 10 of 15703